1,721,208 research outputs found
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety
No full textAtrial fibrillation (AF), the most prevalent cardiac arrhythmia, is estimated to affect 1.5% to 2.0% of the general population, that is, at least 100 million people worldwide.1 Left untreated, patients with nonvalvular AF (NVAF) are exposed to an annual risk of thromboembolic stroke of ≈5%, resulting in 5 million AF-related strokes each year.1 Properly dosed anticoagulation (eg, warfarin adjusted to an international normalized ratio of 2.0–3.0) is extremely effective in preventing AF-related strokes, reducing risk by two thirds compared with no therapy and by one-half compared with aspirin.1 In contrast, aspirin alone achieves a 21% relative reduction in risk of nonfatal stroke compared with no treatment, and aspirin plus clopidogrel yields an additional 11% reduction compared with aspirin alone.1 Thus, anticoagulation is the unchallenged current treatment of choice for patients with NVAF at moderate to high risk of thromboembolic complications
Direct oral anticoagulants for ventricular thrombus resolution: pilot trials show reassuring efficacy and safety compared to warfarin
No full textN/
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor
No full textN/
The strengths and frailties of women with cardiovascular disease
No full textShakespeare and popular belief have
tended to reinforce the view that females
are weak. Scientific methodology applied
to the field of cardiovascular disease suggests,
to the contrary, that women are
strong and enduring. Compared to males,
females live at least 4 years longer, develop
ischemic heart disease about 10 years
later, require more risk factors before
manifesting heart disease5, are less subject
to sudden cardiac death6, and appear to
have a more favorable outcome after the
onset of heart failure
- …
